Breast Cancer Research and Treatment

, Volume 131, Issue 2, pp 663–670 | Cite as

Use of high technology imaging for surveillance of early stage breast cancer

  • K. S. Panageas
  • C. S. Sima
  • L. Liberman
  • D. Schrag
Epidemiology

Abstract

Guidelines do not support utilization of high technology radiologic imaging (HTRI) for surveillance after curative treatment for early stage breast cancer. Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data were used to identify 25,555 women diagnosed with stage I–II breast cancer between 1998 and 2003 who survived ≥48 months from diagnosis without evidence of second primary or recurrent cancer in this interval. HTRI utilization (computerized tomography scanning (CT), bone scan (BS), breast magnetic resonance imaging, and positron emission tomography scans) was measured in months 13–48 post-diagnosis. Cases were individually matched to 75,669 female Medicare enrollees without cancer. Factors associated with HTRI utilization were evaluated. Forty percent of women with stage I–II breast cancer and 25% of controls had ≥1 HTRI during the surveillance interval (P < 0.001). High utilization rates were observed for CT (30%) and BSs (19%). The proportion of women who had a CT during the surveillance period increased in both cancer survivors and controls. Among breast cancer cases age <80, higher comorbidity index, stage II disease, and more recent diagnosis were independently associated with receipt of HTRI. Paralleling patterns observed in controls, HTRI utilization for surveillance following diagnosis of early stage breast cancer has steadily increased among Medicare beneficiaries. Strategies to foster judicious utilization of HTRI should be a priority.

Keywords

Breast cancer surveillance High technology imaging SEER-Medicare 

References

  1. 1.
    Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Cancer intervention and surveillance modeling network (CISNET) collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRefGoogle Scholar
  2. 2.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y, Early Breast Cancer Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366:2087–2106PubMedGoogle Scholar
  3. 3.
    Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds) (2011) SEER Cancer Statistics Review, 1975–2002. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2002/. Accessed 27 Aug 2011
  4. 4.
    Rojas M, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli TM, Liberti A (2005) Follow-up strategies for women treated for early breast cancer. Cochrane Library, Oxford, CD001768, ReviewGoogle Scholar
  5. 5.
    Grunfeld E (2009) Optimizing follow-up after breast cancer treatment. Curr Opin Obstet Gynecol 21:92–96PubMedCrossRefGoogle Scholar
  6. 6.
    Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V (1994) Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial—National Research Council Project on Breast Cancer Follow-up. JAMA 271:1593–1597PubMedCrossRefGoogle Scholar
  7. 7.
    Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini P (1999) Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA 281:1586PubMedCrossRefGoogle Scholar
  8. 8.
    The GIVIO Investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 271:1587–1592CrossRefGoogle Scholar
  9. 9.
    US Preventive Services Task Force (2009) Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151:716–726, W-236Google Scholar
  10. 10.
    National Comprehensive Cancer Network (2000) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 11 Jun 2010
  11. 11.
    Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091–5097PubMedCrossRefGoogle Scholar
  12. 12.
    Saslow MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Boetes C, Burke W, Harms S, Leach Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRefGoogle Scholar
  13. 13.
    Loprinzi CL (1994) It is now the age to define the appropriate follow-up of primary breast cancer patients. J Clin Oncol 12:881–883PubMedGoogle Scholar
  14. 14.
    Loprinzi CL, Hayes D, Smith T (2000) Doc, shouldn’t we be getting some tests? J Clin Oncol 18:2345–2348PubMedGoogle Scholar
  15. 15.
    Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ (2007) Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 25:1074–1081PubMedCrossRefGoogle Scholar
  16. 16.
    Report to the Congress: Medicare payment policy. Medicare Payment Advisory Commission. http://www.medpac.gov/documents/Mar06_EntireReport.pdf. Accessed 25 Aug 2011
  17. 17.
    Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA (2010) Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999–2006. JAMA 303:1625–1631PubMedCrossRefGoogle Scholar
  18. 18.
    Brenner DJ, Hall EJ (2007) Computed tomography—an increasing source of radiation exposure. N Engl J Med 357:2277–2284PubMedCrossRefGoogle Scholar
  19. 19.
    Scientists say FDA ignored radiation warnings. NY Times 28 Mar 2010Google Scholar
  20. 20.
    National Cancer Institute. SEER-Medicare: medicare enrollment and claims data. http://www.healthservices.cancer.gov/seermedicare/medicare. Accessed 27 Aug 2010
  21. 21.
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 Supplement, pp IV-1–IV-3-18Google Scholar
  22. 22.
    Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732–748PubMedCrossRefGoogle Scholar
  23. 23.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRefGoogle Scholar
  24. 24.
    Romano PS, Roos LL, Jollis JG (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46:1075–1079PubMedCrossRefGoogle Scholar
  25. 25.
    International Classification of Disease. http://www.icd9data.com/. Accessed 27 Mar 2010
  26. 26.
    CPT standard edition: current procedural terminology (2007). American Medical Association Press, ChicagoGoogle Scholar
  27. 27.
    Brennan S, Liberman L, Dershaw DD, Morris E (2010) Breast MRI screening in women with a personal history of breast cancer. Am J Roentgenol 195:510–516CrossRefGoogle Scholar
  28. 28.
    Hillman BJ, Goldsmith JC (2010) The uncritical use of high-tech medical imaging. N Engl J Med 363:4–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • K. S. Panageas
    • 1
  • C. S. Sima
    • 1
  • L. Liberman
    • 2
  • D. Schrag
    • 3
  1. 1.Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Medical OncologyDana-Farber Cancer InstituteBostonUSA

Personalised recommendations